CASI Pharmaceuticals (CASI) announced that the Safety Monitoring Committee has completed its review of cohort 4 along with its continued assessment of the first three cohorts of the company’s Phase 1 dose-escalating and safety study of CID-103 in adults with chronic immune thrombocytopenia. The SMC has recommended that the trial continue and the dose escalation to cohort 5 may proceed as per the protocol design.
Claim 70% Off TipRanks This Holiday Season
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on CASI:
- CASI Pharmaceuticals: Strategic Advancements and Leadership Strengthening Drive Buy Rating with $4.00 Price Target
- CASI Pharmaceuticals Strengthens Board with New Appointment
- Casi Pharmaceuticals appoints Barbara Krebs-Pohl to board of directors
- CASI Pharmaceuticals Reports Q2 2025 Results and Strategic Asset Divestiture
- CASI Pharmaceuticals Faces Setback with FOLOTYN® License Expiration in China